Viralgen specializes in the large-scale manufacturing of adeno-associated virus (AAV) gene therapies, utilizing cutting-edge cGMP (current Good Manufacturing Practice) production facilities. Their capabilities include the operation of multiple independent manufacturing suites, allowing for the simultaneous production of up to seven different products. The company employs single-use stirred-tank bioreactors with capacities of 250L and 500L for clinical manufacturing, and they are currently producing at a scale of 2000L in their commercial facility. This advanced infrastructure is complemented by an in-house quality control laboratory that ensures critical release assays are conducted efficiently.

The proprietary production platform at Viralgen is based on a mammalian cell line, specifically the licensed Pro10™ cell line derived from HEK293 cells, which significantly enhances yield optimization—reportedly by over 70% compared to other cell lines. Their innovative manufacturing process involves a triple transfection method, which is designed to be serum-free and scalable up to 2000L. This approach not only streamlines the production process but also allows for rapid program incorporation, thereby accelerating the development timeline for gene therapies. Viralgen's commitment to quality and efficiency positions them as a leader in the AAV gene therapy manufacturing sector.

Spain

Viralgen is a CDMOfor AAV production that supportslarge-scale manufacturing, fill-finish, and quality control in a GMP-certified environment

Viralgen

Company Details